Program
Caffeine
Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.
Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.
Drug pageCaffeine: every studyMany companies study it; this page follows only the 16 they lead. All 247 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 60 open or running | phase 3since Aug 22, 2013 | Jun 13, 2013 | none ahead |
| GlaxoSmithKlineits history only | 50 open or running | phase 4since Nov 3, 2011 | Mar 1, 2007 | none ahead |
| Pfizer | 20 open or running | phase 3since Aug 8, 2016 | Aug 8, 2016 | none ahead |
| Hypera Pharmaits history only | 10 open or running | phase 3since Jul 28, 2010 | Jul 28, 2010 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2016First study: phase 3 study in PainFirst studyNCT02863575 · 374 enrolled · United States
- Dec 3, 2020Phase 1 study in Healthy ParticipantsNCT04655040 · 12 enrolled · United States
TargetBeta
“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule
Studies
All 2 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04655040Healthy Participants · United States | 1 | Completed | Mar 5, 2021 | 12 |
| NCT02863575Pain · United States | 3 | Completed | Apr 6, 2018 | 374 |
How it is read
Names in the registry
- “Caffeine”, 11 entries
- “caffeine”, 4 entries
- “ibuprofen + caffeine”, 3 entries
- “Paracetamol and Caffeine”, 2 entries
- “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry
Conditions, from the studies’ own filings
- Pain, 5 studies
- Neoplasms, 2 studies
- Pain, Postoperative, 2 studies
- Common Cold, 2 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.